Franklin Parlapiano Turner & Welch LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,071 shares of the company’s stock after buying an additional 371 shares during the quarter. Johnson & Johnson comprises 2.2% of Franklin Parlapiano Turner & Welch LLC’s holdings, making the stock its 20th biggest position. Franklin Parlapiano Turner & Welch LLC’s holdings in Johnson & Johnson were worth $6,986,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its holdings in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd raised its holdings in shares of Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after purchasing an additional 20,528 shares in the last quarter. 67.57% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Up 1.0 %
Johnson & Johnson stock opened at $173.85 on Monday. The company has a market capitalization of $451.83 billion, a P/E ratio of 35.19, a P/E/G ratio of 2.92 and a beta of 0.54. The firm’s fifty day simple moving average is $164.90 and its 200-day simple moving average is $161.14. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.74%. Johnson & Johnson’s payout ratio is presently 96.36%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of research firms recently commented on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, July 31st. Raymond James raised their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Atlantic Securities raised their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $187.00 price objective on shares of Johnson & Johnson in a research note on Friday, July 21st. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $171.80.
Get Our Latest Research Report on JNJ
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 8/7 – 8/11
- How to Invest in Casino Stocks
- 3 Retailers To Watch Closely Next Week
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
